WO2010032899A3 - Anticorps humain eno1-spécifique - Google Patents

Anticorps humain eno1-spécifique Download PDF

Info

Publication number
WO2010032899A3
WO2010032899A3 PCT/KR2008/006116 KR2008006116W WO2010032899A3 WO 2010032899 A3 WO2010032899 A3 WO 2010032899A3 KR 2008006116 W KR2008006116 W KR 2008006116W WO 2010032899 A3 WO2010032899 A3 WO 2010032899A3
Authority
WO
WIPO (PCT)
Prior art keywords
human antibody
eno1
specific human
present
cancer
Prior art date
Application number
PCT/KR2008/006116
Other languages
English (en)
Other versions
WO2010032899A2 (fr
Inventor
Young Woo Park
Kwang-Lae Hoe
So-Young Choi
Ji Hyun Park
Eun-Jung Song
Jung Yu
Myung-Ho Sohn
Sungsub Kim
Myeoung Hee Jang
Dong-Jin Kim
Original Assignee
Korea Research Institute Of Bioscience And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute Of Bioscience And Biotechnology filed Critical Korea Research Institute Of Bioscience And Biotechnology
Publication of WO2010032899A2 publication Critical patent/WO2010032899A2/fr
Publication of WO2010032899A3 publication Critical patent/WO2010032899A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un anticorps humain spécifique de l'alpha-endolase (ENO1), et plus particulièrement un anticorps humain comprenant une région déterminant la complémentarité (CDR) et une région de charpente (FR) dérivé d'un anticorps humain lié spécifiquement à ENO1. L'anticorps humain ENO1-spécifique exprimé dans les différents types de cellules cancéreuses de la présente invention peut être utilisé dans le diagnostic du cancer, la classification de la maladie, la visualisation, le traitement et l'évaluation pronostique.
PCT/KR2008/006116 2008-09-22 2008-10-16 Anticorps humain eno1-spécifique WO2010032899A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0092736 2008-09-22
KR1020080092736A KR100910962B1 (ko) 2008-09-22 2008-09-22 Ｅｎｏ１―특이적인 인간항체

Publications (2)

Publication Number Publication Date
WO2010032899A2 WO2010032899A2 (fr) 2010-03-25
WO2010032899A3 true WO2010032899A3 (fr) 2010-07-15

Family

ID=41209526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/006116 WO2010032899A2 (fr) 2008-09-22 2008-10-16 Anticorps humain eno1-spécifique

Country Status (2)

Country Link
KR (1) KR100910962B1 (fr)
WO (1) WO2010032899A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449881B2 (en) * 2010-01-28 2013-05-28 Taipei Medical University Anti-α-enolase I antibodies for diagnosis and treatment of α-enolase I-associated diseases
TWI468176B (zh) * 2010-01-28 2015-01-11 Univ Taipei Medical 診斷及治療α－異烯醇酶（α－ｅｎｏｌａｓｅ）相關疾病之抗－α－異烯醇酶抗體
KR102438838B1 (ko) * 2013-01-18 2022-09-02 서울대학교산학협력단 류마티스 관절염 진단용 바이오마커
TWI572358B (zh) 2013-12-20 2017-03-01 財團法人生物技術開發中心 α－烯醇化酶特異性抗體及其使用在免疫疾病之方法
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
US9527922B2 (en) * 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
ES2823798T3 (es) * 2014-12-31 2021-05-10 Dev Ct Biotechnology Anticuerpos humanizados específicos de alfa-enolasa y procedimientos de usos en la terapia del cáncer
JP6786722B2 (ja) * 2016-08-05 2020-11-18 ワイ−バイオロジクス・インコーポレイテッド プログラム化された細胞死蛋白質（ｐｄ−１）に対する新規抗体及びその用途
KR20230026983A (ko) * 2020-05-11 2023-02-27 후닐라이프 바이오테크놀로지, 인코포레이트 알파-엔올라아제 항체들을 포함하는 약물 접합체 및 그의 이용

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58198758A (ja) * 1982-05-15 1983-11-18 Amano Pharmaceut Co Ltd ヒトエノラーゼの定量方法
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070172487A1 (en) * 2005-12-30 2007-07-26 Neng-Yao Shih Alpha-enolase specific antibody and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58198758A (ja) * 1982-05-15 1983-11-18 Amano Pharmaceut Co Ltd ヒトエノラーゼの定量方法
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070172487A1 (en) * 2005-12-30 2007-07-26 Neng-Yao Shih Alpha-enolase specific antibody and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDRONICOS, N. M. ET AL.: "The human ENO1 gene product(recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1337, no. 1, 4 January 1997 (1997-01-04), pages 27 - 39 *

Also Published As

Publication number Publication date
WO2010032899A2 (fr) 2010-03-25
KR100910962B1 (ko) 2009-08-05

Similar Documents

Publication Publication Date Title
WO2010032899A3 (fr) Anticorps humain eno1-spécifique
WO2011095623A3 (fr) Miarn dans le diagnostic du cancer ovarien
EP3296406A3 (fr) Empreinte arnmi dans le diagnostic de cancer du poumon
WO2007047408A3 (fr) Application de signature promac
WO2011135194A3 (fr) Procédé pour diagnostiquer un risque de diabète de type 1 et prévenir le déclenchement d'un diabète de type 1
WO2011100541A3 (fr) Compositions et procédés de détection de petits arn
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
EP2199306A3 (fr) Anticorps humain spécifique VEGF
WO2011062997A3 (fr) Anticorps monoclonaux humains pour nucléoline humaine
WO2006138275A3 (fr) Compositions et procedes de traitement et de diagnostic de cancer
WO2009059150A3 (fr) Biomarqueurs de la stéatose hépatique et procédés les utilisant
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
WO2010056374A3 (fr) Procédés et compositions de profilage moléculaire pour le diagnostic de maladies
WO2010004591A3 (fr) Variantes génétiques pour l'évaluation du risque de cancer du sein
WO2007118214A3 (fr) Compositions d'anticorps et méthodes de traitement d'une maladie néoplasique
WO2010108128A3 (fr) Procédé et système de quantification de la compétence technique
WO2009048538A3 (fr) Anticorps humanisé
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2009048537A3 (fr) Anticorps humanisé
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2008066784A3 (fr) Expression de foxp3 par des cellules cancéreuses
WO2008033427A3 (fr) Compositions et procédés de détection d'une maladie lysosomale
WO2011087709A3 (fr) Translocations d'eml4-alk dans le cancer pulmonaire
WO2013057581A3 (fr) Biomarqueurs composites pour criblage, diagnostic et pronostic non invasifs de cancer colorectal
WO2010044506A3 (fr) Anticorps humain spécifique de tmprss4

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08876997

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08876997

Country of ref document: EP

Kind code of ref document: A2